Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
Q13148 |
TADBP_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
Q13148 |
TADBP_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
Q16665 |
HIF1A_HUMAN |
Adrenomedullary hyperfunction [ICD-11: 5A75] |
Q16665 |
HIF1A_HUMAN |
Brain cancer [ICD-11: 2A00] |
Q16665 |
HIF1A_HUMAN |
Lymphoma [ICD-11: 2A80-2A86] |
Q16665 |
HIF1A_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16665 |
HIF1A_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
P16473 |
TSHR_HUMAN |
Hypo-thyroidism [ICD-11: 5A00] |
P16473 |
TSHR_HUMAN |
Thyroid cancer [ICD-11: 2D10] |